First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia

American Journal of Cancer Research

Zheng Li¹  Ting Xu²  Fengtao You³  Lin Yang⁴  Xiaowen Tang⁵  Haiping Dai⁶  Ansel P Nalin⁷  Jia Yin⁸ 

[1] Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA;Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA;Institute of Blood and Bone Marrow Transplantation, Suzhou, China;Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;Persongen BioTherapeutics Co., Ltd., Suzhou, China;The Cyrus Tang Hematology Center, Soochow University, Suzhou, China;The James Cancer Hospital, The Ohio State University, Columbus, OH 43210, USA

关键词: CAR NK-92 cells;    CD33;    safety test;    relapsed;    refractory;    acute myeloid leukemia;   

DOI  :  

学科分类：肿瘤学

来源: e-Century Publishing Corporation

【 摘 要 】

CAR T cells have shown clinical efficacy for acute lymphoblastic leukemia, but this therapy has not been effective for acute myeloid leukemia (AML), and other treatment options are needed. Theoretically, CAR-NK cells have a more favorable toxicity profile compared to CAR T cells, especially in avoiding adverse effects such as cytokine release syndrome. However, the clinical evidence for this has not yet been reported. In the current study, we tested the safety of CD33-CAR NK cells in patients with relapsed and refractory AML. At doses up to 5 × 109 (5 billion) cells per patient, no significant adverse effects were observed. CAR NK-92 cells can be produced at much lower cost compared to CAR T cells, and we believe after being optimized, they will be widely accessible for the treatment of cancer.

【 授权许可】

CC BY-NC